Aquestive Therapeutics (AQST) Payables (2017 - 2025)
Historic Payables for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $10.9 million.
- Aquestive Therapeutics' Payables rose 4348.92% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 4348.92%. This contributed to the annual value of $10.3 million for FY2024, which is 1524.76% up from last year.
- Latest data reveals that Aquestive Therapeutics reported Payables of $10.9 million as of Q3 2025, which was up 4348.92% from $12.0 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Payables peaked at $12.4 million during Q1 2023, and registered a low of $5.7 million during Q2 2024.
- Over the past 5 years, Aquestive Therapeutics' median Payables value was $9.9 million (recorded in 2022), while the average stood at $9.4 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Payables crashed by 5921.11% in 2021, and later surged by 10981.39% in 2025.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Payables stood at $8.3 million in 2021, then increased by 19.63% to $9.9 million in 2022, then decreased by 10.26% to $8.9 million in 2023, then rose by 15.25% to $10.3 million in 2024, then grew by 5.62% to $10.9 million in 2025.
- Its Payables was $10.9 million in Q3 2025, compared to $12.0 million in Q2 2025 and $12.3 million in Q1 2025.